BioCentury | Sep 10, 2007
Company News

Eden Biodesign, Cancer Research UK deal

...therapy to treat intra-abdominal cancer in combination with the prodrug CB1954; and Ad.CPG2, which expresses carboxypeptidase G2...
BioCentury | Feb 2, 2004
Company News

Protherics sales and marketing update

...PTI began supplying Voraxaze carboxypeptidase G2 on a "named patient" basis in Europe as a rescue therapy...
BioCentury | Sep 1, 2003
Clinical News

Voraxaze carboxypeptidase G2 regulatory update

...testing, received European Orphan Drug designation in February. Protherics plc (LSE:PTI), Macclesfield, U.K. Product: Voraxaze carboxypeptidase G2...
BioCentury | Feb 24, 2003
Clinical News

Carboxypeptidase G2 regulatory update

...The EMEA granted Orphan Medicinal Product designation to Carboxypeptidase G2 for use as an adjunctive treatment in...
...treatment in patients at risk of methotrexate toxicity. Enact Pharma plc (OFEX:Enact), Abingdon, U.K. Product: Carboxypeptidase G2...
BioCentury | May 3, 1999
Company News

Epttco Ltd., Vion deal

...genetically engineered Salmonella bacteria, to deliver Epttco prodrug activation technology, which uses either nitroreductase or carboxypeptidase G2...
Items per page:
1 - 5 of 5